Similarly, KRAS G12C inhibitors led to an enhanced influx and activation of CD8+ T cells, polarization of the myeloid compartment, increased antigen presentation, and upregulation of transcriptional programs associated with IFN signaling, changes that may boost the tumor responses driven by checkpoint blockade [152]. The gene discussed is CD8A; the disease is neoplasm.